CNL Launches Annual Call for Proposals for its Joint Research Program in Health
Launched in 2021, the CNRI-H program was established to accelerate the development of targeted radiopharmaceuticals for the benefit of Canadians through joint research projects, by providing access to the world-class laboratories and research capabilities at the Chalk River Laboratories campus.
- Launched in 2021, the CNRI-H program was established to accelerate the development of targeted radiopharmaceuticals for the benefit of Canadians through joint research projects, by providing access to the world-class laboratories and research capabilities at the Chalk River Laboratories campus.
- CNL recently announced the first recipient under the CNRI-H program , which will see the company collaborate with a leading radiopharmaceutical company, Jubilant Radiopharma, on the development of novel alpha radiopharmaceuticals.
- CNL will complete a final evaluation of the proposed project plans before making the final selection and approval of successful applicants.
- For more information on the CNRI Health Stream, including submission guidelines and details, please visit www.cnl.ca/cnri-health .